The Qatar Investment Authority (QIA) has become a major investor in a $132 million Series B funding round.
The funding supports Artbio, a biotech company developing advanced radiopharmaceutical treatments currently in the clinical stage.
This is the Qatar Investment Authority’s first investment in the US-based company, Artbio.
Artbio is developing a new type of cancer treatment called alpha radioligand therapies (ARTs), designed to target and treat various forms of cancer.
Artbio said the Series B funding round was led by Sofinnova Investments and B Capital, along with a returning life sciences investment fund.
Additional support came from existing investors like F-Prime, Omega Funds, and Third Rock Ventures, as well as new investor Alexandria Venture Investments.
The company said the proceeds will be used to advance its development of ARTs.
QIA, managing $524 billion in assets, has been gradually increasing its investments in U.S. biotech companies.
In 2023, it led a $250 million funding round for BridgeBio Pharma, a Nasdaq-listed firm focused on genetic diseases and cancer treatments.
Read more- Singapore’s Hydroleap Raises $4.75M to Grow Eco-Friendly Water Tech in Asia
